Cronobe

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cronobe

What is Cronobe? Defining Composition and Purpose

Property Description
Active ingredient Cyanocobalamin (Vitamin B12)
Form Solution for injection (Ampoules), Oral Tablets
Pharmacological class Water-Soluble Vitamin, Antianemic Agent
Common use Supplementation for B12 deficiency
Origin Synthetic (Man-made) Compound

Defining Cronobe: Composition and Pharmacological Class

Cronobe is a pharmaceutical preparation whose primary active component is Cyanocobalamin, which is scientifically classified as an essential Water-Soluble Vitamin and, functionally, an Antianemic agent. This compound is a synthetic (man-made) version of the naturally occurring essential nutrient Cobalamin, also known as Vitamin B12. This means the medicine is manufactured to provide the vital B12 structure that the body cannot produce itself. Cronobe is widely known for being available as an injectable solution (ampoules), a common presentation used when reliable delivery is required for patients with severe deficiency. This replacement therapy is clinically recognized for correcting low levels of the vitamin in the blood, a general use scenario broadly supported by pharmacological studies.


Cronobe's Core Function and Available Forms

The core function of the Cyanocobalamin in Cronobe is to serve as an essential cofactor, supporting two processes critical to human physiology: the formation of red blood cells and the maintenance of the nervous system. This capability is intrinsically linked to its role in facilitating DNA synthesis and preserving the integrity of the myelin sheath that insulates nerve fibers. The general benefit, therefore, is the fundamental support of cell reproduction and optimal nerve cell health generally. The medicine is available as an aqueous solution for injection—often administered via the parenteral route—and as oral tablets. The injectable form is frequently used when absorption issues compromise the effectiveness of the oral route, ensuring the vital B12 structure is reliably delivered.

What side effects are possible with Cronobe?

Possible Side Effects and Safety Information

The safety profile for Cronobe (Cyanocobalamin) is officially documented by regulatory authorities, with adverse reactions generally classified by the physiological system they affect. The frequency of most reported side effects is typically categorized as "Not known" in official documents, meaning precise incidence rates cannot be estimated from the available data.


Adverse Reactions and Systemic Groupings

Adverse effects listed in official labeling include reactions within the Immune System, Cardiovascular System, Skin and Subcutaneous Tissue, and the Gastrointestinal System. Common documented effects include transient diarrhea, itching (pruritus), and temporary skin rash (exanthema), alongside reactions at the injection site such as pain or swelling.

Serious Adverse Reactions

Regulatory warnings highlight rare but clinically significant adverse reactions. These include severe hypersensitivity events, such as anaphylactic shock and associated fatalities, pulmonary edema, and congestive heart failure. The risk of severe hypokalemia (low potassium), which can lead to cardiac arrhythmias, is also noted, especially during the initial intensive phase of therapy for severe megaloblastic anemia.


Population-Specific Safety Constraints

The official label mandates specific constraints for certain populations. Cyanocobalamin is strictly contraindicated in individuals with known Leber's hereditary optic atrophy, as it may worsen the condition. Precautions are also necessary for patients with impaired renal function due to the potential for aluminum accumulation in parenteral formulations. Furthermore, the product is contraindicated for those with a known sensitivity to cobalt or to any component of the formulation.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Cronobe's active component, Cyanocobalamin, states that it is a water-soluble vitamin, and acute toxicity is unlikely from high doses, as excess amounts are readily excreted from the body. Documented overdose presentations are typically limited to minor and transient effects, such as mild diarrhea or a temporary rash.

Required Emergency Actions

Despite the low risk of acute toxicity, regulatory authorities have documented the potential for severe, life-threatening outcomes, particularly associated with parenteral (injectable) administration. These serious manifestations include reports of anaphylactic shock and death, as well as cardiovascular compromise such as pulmonary edema and congestive heart failure, and the development of peripheral vascular thrombosis (blood clots).

Immediate medical attention is required upon the manifestation of any signs indicative of severe hypersensitivity or cardiovascular distress. Management relies on symptomatic and supportive treatment, as no specific antidote is documented in official sources.

Monitoring and Special Considerations

Monitoring of specific parameters, including serum potassium levels and platelet count, is required during the intensive correction of severe deficiency. A specific population consideration is the contraindication for use in patients with early Leber's disease due to the regulatory-documented risk of causing severe and swift optic atrophy.

Therapeutic Uses of Cronobe

Main Uses and Benefits of Cronobe

Cronobe is a pharmacological formulation of Vitamin B12 (Cyanocobalamin) indicated for the treatment and prevention of deficiency states. This medication plays a critical role in maintaining metabolic processes, neurological function, and hematological health.

Treatment of Vitamin B12 Deficiency

The primary use of Cronobe is to address low levels of Vitamin B12 in the body. This deficiency can arise from various factors, including:

  • Inadequate Dietary Intake: Often observed in individuals following strict diets that exclude animal products without appropriate supplementation.
  • Malabsorption Syndromes: Conditions where the digestive system cannot effectively absorb the vitamin from food, such as certain gastric or intestinal disorders.
  • Increased Physiological Demand: Periods where the body requires higher amounts of the vitamin than usual.

Hematological Benefits

Vitamin B12 is essential for the synthesis of DNA and the proper maturation of red blood cells. By correcting a deficiency, Cronobe helps restore healthy red blood cell production, which is necessary for efficient oxygen transport throughout the body. This process is vital in managing megaloblastic anemia, a condition characterized by the production of abnormally large and dysfunctional red blood cells.

Neurological Support

The nervous system relies on Vitamin B12 for the maintenance of the myelin sheath, the protective coating that surrounds nerve fibers. Adequate levels of the vitamin support:

  • Nerve Signal Transmission: Ensuring efficient communication between the brain and the rest of the body.
  • Cognitive Health: Maintaining functions related to memory and mental clarity.
  • Prevention of Nerve Damage: Reducing the risk of peripheral neuropathy associated with long-term deficiency.

Metabolic Function

Cronobe contributes to general cellular metabolism. Vitamin B12 acts as a cofactor for enzymes involved in the metabolism of fatty acids and amino acids. By facilitating these biochemical reactions, the medication helps the body convert nutrients into energy and maintain healthy homocysteine levels, which is important for cardiovascular and systemic health.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility and Contraindications for Cronobe

The eligibility profile for Cronobe (Cyanocobalamin) is determined by official regulatory documents, which define absolute exclusions and specific restrictions for certain populations.

Category Official Regulatory Statements
Populations Contraindicated Sensitivity to Vitamin B12 or Cobalt is an absolute contraindication. Use is also forbidden in patients with Early Leber's Disease (hereditary optic nerve atrophy).
Populations Allowed The medicine is indicated for individuals with a confirmed Vitamin B12 deficiency [1.4, 1.7].
Age-Related Restrictions Injectable formulations containing the preservative Benzyl Alcohol must be used cautiously in premature infants and neonates due to the associated risk of serious toxicity [1.4, 1.7].
Conditional Restrictions Patients with impaired kidney function (renal impairment) require special caution, particularly with prolonged parenteral administration, due to the documented risk of aluminum accumulation [1.4]. The co-existence of folate deficiency necessitates careful monitoring, as high doses of B12 can mask the blood-related symptoms of the folate deficiency [1.4, 1.7].
Pregnancy/Lactation Use is permitted during pregnancy and lactation at therapeutic doses, as it is an essential nutrient and no adverse effects are reported in the infant [1.7].

These official regulatory statements define who must not use the medicine and establish conditional limitations for patients with specific health conditions or age factors.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information identifies specific drug and substance interactions that affect the efficacy and levels of the components in Cronobe ( V itamin , B1, B6, B12).

Contraindicated and High-Risk Combinations

  • Levodopa: Co-administration is restricted/forbidden in patients with Parkinson's disease who are using levodopa, as the V itamin , B6 component reduces the therapeutic effect of levodopa.
  • Alcohol: Ingestion of alcoholic beverages is officially required to be avoided during the treatment period.

Substances Modifying Vitamin Exposure

The absorption of V itamin , B12 is officially noted to be decreased by various drugs, including Salicylates, Colchicine, Isoniazid, Aminoglycosides, Methotrexate, and Anticonvulsants (e.g., phenytoin). Separately, the V itamin , B6 component is inactivated by co-administration with Tetracycline, Erythromycin, Penicillin, and Para-aminosalicylic acid.

Pharmacodynamic and Diagnostic Interference

  • Folic Acid: Continuous high doses of Folic Acid are officially noted to mask the symptoms of V itamin , B12 deficiency, which is relevant to diagnosis and monitoring.
  • Chloramphenicol may officially antagonize the hematopoietic response to V itamin , B12 used for anemia treatment.

Population-Specific Constraints

Use of the complex formulation is contraindicated in children under 12 years of age and in patients with Leber's disease (hereditary optic nerve atrophy).

Mechanism of Action

Cronobe's mechanism of action is an essential cofactor replacement that operates by restoring the function of two critical enzymes, directly linking molecular action to systemic physiological processes. This mechanism facilitates cellular replication processes and contributes to the maintenance of neurological structure. The active coenzyme, extbfMethylcobalamin, functions as a cofactor for the extbfMethionine Synthase enzyme. By activating this enzyme, the drug facilitates the metabolic regeneration of active Folate, which is indispensable for extbfDNA synthesis. This action restores the synthesis process, leading to the support of blood cell maturation (hematopoiesis). Concurrently, the second active coenzyme, extbfAdenosylcobalamin, is required by the extbfL-Methylmalonyl-CoA Mutase enzyme. This activation facilitates the conversion of extbfMethylmalonyl-CoA, thereby mitigating the accumulation of extbfMethylmalonic Acid ( extbfMMA). The enzyme's activity is required for the structural maintenance of the myelin sheath and neuronal stability. The function of this mechanism in the extbfDNA synthesis pathway is interdependent with the concurrent presence of Folate, and the administered extbfCyanocobalamin must undergo a metabolic conversion step before engaging its target enzymes, which determines the kinetics of its coenzyme action.

Dosage and Administration Information

How to use Cronobe — Official Administration Guidelines

Official guidelines for the administration of a product named Cronobe are not documented. Therefore, no official administration procedures can be extracted for this product.


Administration Scope

Parameter Official Administration Instruction
Route of administration Not officially documented.
Dosing schedule Not officially documented.
Timing in relation to meals Not applicable; official timing is not documented.
Preparation requirements Not applicable; official preparation steps are not documented.
Age-group administration rules Not officially documented.
Missed-dose rules Not officially documented.
Special procedural conditions No official procedural steps are documented.

Instruction Classifications (High-Level)

Classification Official Regulatory Basis
Administration method type Not applicable; official administration method is not documented.
Frequency pattern Not applicable; official frequency is not documented.
Regulatory basis No recognized official drug label for this product name.
Use-context constraints None documented for a product named Cronobe.

Connection to the Overall Use Protocol

Documentation does not contain an official protocol or step-by-step administration guide for a pharmaceutical product named Cronobe. Consequently, the complete administration map is unavailable, as the necessary official parameters—including route, dose, and preparation—are not present. The absence of a registered drug label confirms that an official administration guideline cannot be provided.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cronobe (Cyanocobalamin)


Research Evidence for Correcting Overt B12 Deficiency

Research has explored populations with confirmed low Vitamin B12 levels in the blood, often due to conditions like Pernicious Anemia or various malabsorption disorders. Randomized Controlled Trials (RCTs) and systematic reviews have monitored how different administration methods, such as injections (like Cronobe) versus high-dose oral tablets, compare in an effort to evaluate a person's B12 status. Studies monitored blood markers like serum B12 and functional markers such as methylmalonic acid (MMA) and homocysteine, which are used to evaluate B12 status.

Findings describe patterns observed in the studies, including the measurement of increased B12 concentrations in the blood following the start of replacement therapy. Trials described patterns related to the shift in levels of MMA and homocysteine, which are biomarkers used to monitor B12 status. Research highlights changes measured during the study period related to red blood cell parameters, which reflect the status of blood formation, and are associated with the resolution of megaloblastic anemia.

While B12 replacement has a long history, data are still emerging related to the optimal long-term strategy in contemporary research. For instance, sample sizes were modest in some head-to-head trials comparing the injection and high-dose oral options for the initial correction phase. Comparative evidence is lacking for how the specific compound Cyanocobalamin relates to other types of B12 compounds in all patient groups.


Studies Addressing Neurological Symptoms of Deficiency

This part reviews the available evidence from RCTs, observational studies, and case reports that examined the impact of therapy on neurological symptom scores, including issues related to balance, sensation, and cognitive function. Outcomes related to patient-reported outcomes describing perceived discomfort were studied for patients reporting symptoms like numbness, tingling, and chronic fatigue.

Research highlights changes measured during the study period, where reports described patterns related to the evolution of neurological symptoms. Studies report how symptoms evolved in the observed populations, sometimes including changes in gait, sensation, and concentration following the start of replacement therapy. Observations often described that the timing and degree of reported symptom changes were measured to vary between patients, especially when symptoms were long-standing.

High-quality RCTs focusing exclusively on long-term neurological endpoints are limited, with much of the extended duration data derived from observational settings. Data for certain groups remain insufficient regarding how replacement therapy affects neurological symptoms in patients with only mild or subclinical B12 deficiency. The extent to which long-standing neurological damage can be fully reversed remains an area of ongoing study.

Key Studies & References

  1. Efficacy of Sublingual and Oral Vitamin B12 Versus Intramuscular Administration: Insights from a Systematic Review and Meta-Analysis
  2. Cyanocobalamin - StatPearls (NCBI Bookshelf - NIH)

Frequently Asked Questions (FAQ)

Common questions about Cronobe (FAQ)

Q: Why do some people say Cronobe makes them tired?

Regulatory documents listing possible adverse reactions for this type of medication have reported effects such as unusual tiredness or weakness and extreme fatigue. However, the frequency or chance of these effects happening is often listed as 'Incidence not known' by official sources.


Q: Can Cronobe cause long-term side effects that official documents mention?

Official product information does not define a category for 'long-term side effects.' However, for the injectable form, regulatory documents highlight the risk of aluminum accumulation with prolonged parenteral use (injection) in individuals who have impaired kidney function.


Q: Is Cronobe safe for older adults to use?

Official information indicates that B12 deficiency, the condition Cronobe treats, is more prevalent in adults aged 60 and older. While the product itself is not contraindicated based on age, official guidance notes that the injection route can be inconvenient for elderly persons. The determination of use is based on the healthcare provider’s assessment of the individual’s deficiency.


Q: Is it normal to feel a mild headache when first starting Cronobe?

Regulatory documents listing adverse reactions have reported headache as a possible effect related to this medication. As with many other possible effects, the precise frequency or chance of a headache occurring is typically listed as 'Incidence not known' in official product information.


Q: Does Cronobe affect blood pressure or heart rate?

Official documents list several adverse reactions that involve the cardiovascular system. These include reports of fast heartbeat, irregular heartbeat, low blood pressure, and chest pain. Rare but serious reactions, such as congestive heart failure and pulmonary edema (fluid in the lungs), are also noted.


Q: Are there restrictions on driving or operating machinery while on Cronobe?

The official product information for cyanocobalamin, the active ingredient, explicitly states that it has no or negligible influence on the ability to drive and use machines. Patients should consider their individual response to the medication, as official labeling reports no known influence.


Q: What should I do if I notice a rash after starting Cronobe?

Official documentation states that symptoms like rash, hives, or swelling should be communicated to a healthcare professional, as they can indicate a hypersensitivity reaction. The appearance of a rash may be a sign of a serious allergic reaction.


Q: Can Cronobe be used by people who have existing liver conditions?

While specific liver conditions are not typically listed as absolute contraindications in regulatory documents, official clinical guidance suggests caution is necessary when interpreting B12 test results in patients who have liver disease. Conditional use, like use in patients with liver conditions, is subject to the review and guidance of a healthcare professional.


Q: Are there any concerns about taking Cronobe with birth control pills?

Current authoritative drug interaction databases indicate that no interactions have been found between Vitamin B12 and common progestin-only oral contraceptives. Patients are generally advised to inform their healthcare professional about all concurrent medicines and supplements to ensure a complete interaction profile.


Q: Is it typical for side effects from Cronobe to go away after a few weeks?

Some listed side effects, such as transient diarrhea, are described in regulatory documents as mild and transient, which suggests they may resolve quickly. For other effects, official guidance notes that adjustment to the medicine is required, though no specific time frame like 'a few weeks' is provided.


Q: Are there any known interactions between Cronobe and herbal supplements like St. John's Wort?

Regulatory agencies note that unlike prescription medicines, herbal remedies and supplements are typically not tested for interactions with drugs like Cronobe. Regulatory agencies emphasize the importance of communicating all herbal products and supplements being used to the prescribing healthcare professional.


Q: Can Cronobe cause changes in weight?

Yes, official documents list weight gain as a side effect that may occur while using this type of medication. The frequency of this effect, however, is generally listed in official product information as 'Incidence not known'.


Q: Is Cronobe associated with any mental health side effects, such as anxiety?

Mental health effects are not typically listed in the adverse reaction sections of official product information. However, authoritative health guidance notes that B12 deficiency itself is associated with psychiatric disturbances and cognitive decline in some individuals.


Q: How quickly does Cronobe leave the body after the last dose?

The elimination of the drug from the bloodstream can be relatively rapid, though the half-life varies significantly depending on the route of administration and individual biological factors. The elimination kinetics are complex.


Q: Where can I find the official regulatory information about Cronobe?

Official product information, such as the Summary of Product Characteristics (SmPC) or the FDA Drug Labeling, can be found in the public records of drug authorities. These sources are typically listed under the active ingredient name, Cyanocobalamin.


Q: Is Cronobe a drug that needs to be taken long-term?

Clinical guidance often suggests that high-dose B12 supplementation, which includes oral and injectable forms, may be considered for long-term treatment in patients with established, chronic B12 deficiency. The requirement for long-term use is generally linked to the specific underlying cause of the B12 deficiency.


Q: Are there different forms or strengths of Cronobe available?

Yes, in addition to the injectable solution and oral tablets, Cyanocobalamin is available in various tablet strengths, often ranging from 100mu g up to high-dose options like 1000mu g or more. Other forms, such as a nasal spray, are also occasionally available.


Q: What are the main research findings about Cronobe's effectiveness?

Studies confirm that Cyanocobalamin corrects B12 deficiency in the blood and leads to the improvement of symptoms and laboratory abnormalities associated with pernicious anemia and other deficiency states. This includes improving red blood cell indices and patterns related to neurological damage.


Q: Is Cronobe used to treat pain?

While not listed as a primary indication for treating pain, Cyanocobalamin is sometimes included in combination products used for the treatment of diabetic neuropathies and nerve conditions. Its role is as an essential cofactor for maintaining neurological structure.


Q: How is the safety of Cronobe monitored after it's been approved?

Post-approval safety is monitored by regulatory authorities through patient and professional reporting systems. Patients are encouraged to report any suspected side effect using national safety schemes, such as the Yellow Card scheme (UK) or similar official safety reporting systems.


Q: Does Cronobe cause sleep problems?

Regulatory documents listing adverse reactions for this type of medication have reported drowsiness as a possible effect. However, the exact frequency of this effect is typically listed as 'Incidence not known' in official product information.


Q: Can I take Cronobe if I have a known allergy to similar drugs?

Official product information strictly contraindicates (prohibits) the use of Cronobe in individuals who have a known sensitivity to cobalt or to vitamin B12 itself. The use of the product requires evaluation by a healthcare professional regarding any known allergies to related drugs or excipients.


Q: Is it necessary to have a physical exam before starting Cronobe?

Authoritative clinical guidance suggests that before starting B12 deficiency treatment, a thorough patient evaluation should include a complete history and physical exam. This is particularly important to check for neurological and gastrointestinal symptoms related to the deficiency.


Q: What does 'contraindication' mean in the context of Cronobe?

A contraindication is a medical condition or factor, such as a known sensitivity to cobalt, that strictly prohibits the use of the medicine. Regulatory bodies state that the risk associated with use when a contraindication is present outweighs any potential benefit.


Q: Are there any special warnings for people with diabetes taking Cronobe?

Authoritative clinical studies highlight that individuals with Type 2 Diabetes who are using the drug metformin are at a known risk of developing B12 deficiency. The need for B12 supplementation for these individuals may arise and is subject to clinical monitoring.


Q: How is the use of Cronobe generally monitored by healthcare professionals?

Official labeling and clinical guidance state that monitoring involves tracking key markers, such as serum B12, methylmalonic acid (MMA), and homocysteine levels. Additionally, serum potassium is checked closely, particularly during the initial phase of treatment for severe deficiency.

How should Cronobe be stored and disposed of?

Official Storage and Disposal Requirements

Cronobe (Cyanocobalamin) must be stored strictly according to the conditions defined in the official regulatory labeling.

Storage Component Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C), with excursions permitted up to 30 C (86 F). Do not freeze.
Protection Must be protected from light and kept in the original container to maintain stability.
Child Safety Keep the medicine out of the sight and reach of children.
In-Use Stability Once a multiple-dose vial is first opened, any unused portion must be discarded after 30 days.

Used needles, syringes, and empty vials must be immediately placed in a specialized sharps disposal container. Unused or expired product must be disposed of according to local, state, and federal regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cronobe found in:

A-Z Index: